Aripiprazole Tablet
Product Images NDC 70518-2281

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2281). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 10mg 70518 2281 02

This description is about Aripiprazole 10mg tablets with a quantity of 30 tablets. The tablets are white and rectangular in shape. The medication is repackaged by RemedyRepack Inc. and the original NDC is 62332-0099-31. The manufacturer is Alembic Pharma located in Bridgewater, NJ 08807. It is advised to keep the medication out of reach of children and store it at temperatures between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP guidelines.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

FDA Label Image

Aripiprazole Fig 6

This text appears to provide data on the proportion of subjects experiencing a relapse over time in a study comparing Aripiprazole to a placebo. The number of subjects at risk is specified at different time points during the study. The data seems to indicate the progression of relapse rates over 182 days from randomization.*

FDA Label Image

Aripiprazole Fig 9

This text provides data on the Least-Squares Mean Change in YGTSS Total TIC Score over different weeks of treatment with Aripiprazole low dose, Aripiprazole high dose, and placebo.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

This is a table showing the number of subjects at risk over time for Aripiprazole and PLACEBO in relation to the proportion with relapse. The number of subjects at risk decreases over time for both Aripiprazole and PLACEBO, with varying numbers of subjects at different time points. The data appears to be related to a study or trial tracking relapse rates over time from randomization.*

FDA Label Image

Aripiprazole Figure1

This text provides information on the effect of various drugs on Aripiprazole. It lists different drugs, their impact on the metabolism of Aripiprazole, and the relative change in its concentrations when combined with these drugs. The listed drugs include CYP1A inhibitor ketoconazole, CYP2D6 inhibitor suxinidine, a CYP3A4 inducer carbamazepine, and gastric acid blockers such as famotidine. Additionally, it mentions the effect of valproate on Aripiprazole levels. The numbers indicate the fold change and 90% confidence interval for each interaction.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

This text discusses the effect of other drugs on Aripiprazole. It mentions that certain drugs can influence the pharmacokinetics of Aripiprazole, such as CYP enzyme inhibitors and inducers, co-administered drugs like valproate, and gastric acid blockers like famotidine. This information can be useful for healthcare professionals and individuals managing medications containing Aripiprazole.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

Special Populations This text provides information on different special populations that may impact the pharmacokinetics of a medication, such as individuals with poor metabolism, different genders, various ages, hepatic impairments ranging from mild to severe, and renal impairments. The text mentions specific parameters to consider for each population group when evaluating the effect on drug exposure. Additionally, it seems to discuss the fold change and relative changes in exposure of Aripiprazole in these populations.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

FDA Label Image

Structure (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.